vimarsana.com

Page 13 - உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் மாதிரி பட்டியல்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs

Search jobs 17-Mar-2021 Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs cobas® pure integrated solutions brings together three diagnostic technologies 1 on a single platform to optimise space and resources in small to medium laboratory settings With a footprint of just two square meters, this new analyser provides small to medium sized labs with access to more than 230 diagnostic tests 2 across a wide-range of disease areas including infectious diseases, oncology and cardiology Through automation of manual tasks, Roche’s new solution is designed to simplify workflows and improve the productivity of lab personnel whilst also supporting the delivery of better patient care

Investegate |F Hoffmann-La Roche Ltd Announcements | F Hoffmann-La Roche Ltd: Roche Annual General Meeting 2021

Roche Annual General Meeting 2021 All proposals of the Board of Directors approved Christoph Franz re-elected as Chairman of the Board of Directors; all current Board members re-elected 34th consecutive dividend increase to CHF 9.10 per share Basel, 16 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). Owing to the pandemic restrictions, the AGM was held with only those persons required by the Articles of Incorporation in attendance and with no shareholders physically present. Roche shareholders were able to exercise their rights via written or electronically submitted instructions to the independent proxy, Testaris AG. The independent proxy represented 84.58% of the total of 160,000,000 shares. The Management Report, the Annual Financial Statements and the Consolidated Financial Statements for 2020 were approved.

F Hoffmann-La Roche Ltd: New two-year data show Roche s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA)

F Hoffmann-La Roche Ltd: New two-year data show Roche s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

F Hoffmann-La Roche Ltd: Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations

F Hoffmann-La Roche Ltd: Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

New two-year data show Roche s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA) Swiss Stock Exchange:RO

New two-year data show Roche s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA) Swiss Stock Exchange:RO
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.